Google
CNTB 株価分析 — Connect Biopharma Holdings LTD (Healthcare >> Biotechnology)
CNTB に関するよくある質問
CNTBのROE（自己資本利益率）は？
Connect Biopharma Holdings LTDのROEは-151.58%です。
CNTBの配当利回りは？
Connect Biopharma Holdings LTDの配当利回りは0.00%です。
CNTBの品質スコア（Quality Score）は？
当社のAIはCNTBの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CNTBは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CNTBはどのセクターに属しますか？
Connect Biopharma Holdings LTDはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
CNTB AI Analysis Summary
Our AI summary for CNTB: Connect Biopharma Holdings LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -151.58%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.02
Price
-0.07
(-3.35%)
Day Change
|
|
|---|
CNTB, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.02 |
| PBV / Sector |
3.09 / 5.20
|
| Earning Per Share | -0.99 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
1.17 M
GREAT
|
| Average 1W Daily Value |
0.39 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:39 |
| Symbol | CNTB |
| Name | CONNECT BIOPHARMA HOLDINGS LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 62.96 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 131.59 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3580 Carmel Mountain Road, San Diego, CA, United States, 92130
Phone: 877 245 2787
Website: https://www.connectbiopharm.com
Employees: 64
Sector: Healthcare >> Biotechnology
Description: Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
